Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
C. David Weaver
Vanderbilt University, Department: Physiology
Should you be removed from our database? Contact us at [email protected]. Read more below.
WaveFront Biosciences
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Weaver has developed a prototype large format telecentric lens and novel dye technology that is currently licensed to WaveFront, a start-up company in which he is a founder and executive. The Vanderbilt High-Throughput Screening facility has the prototype instrument which is supported by the company through software upgrades. The instrument is used at Vanderbilt by faculty and trainees for research projects. However, they are not involved in the ongoing development of the lens. There has been in place for several years a management plan which includes an internal disclosure process and review for oversight of any business conducted by Vanderbilt with WaveFront Biosciences. Effort allocation logs are required to ensure that there is no utilization of grant resources in the furtherance of the company’s interests. This grant will use a plate reader (Panoptic) made by Wavefront. It is the only such plate reader available to the investigator for the screen and thus is a project requirement. This project may also use a reagent which is licensed to Wavefront and/or that Dr. Weaver may receive royalties from the sales of a 3rd party to whom Vanderbilt has licensed the rights to sell the reagent.
Designing selective TALK-1 inhibitors to reduce beta-cell dysfunction in diabetes
Project Narrative: The discovery of how TALK-1 channels control ?-cell function under physiological and diabetic conditions will determine the therapeutic applicability of targeting this islet-restricted ion channel for treating diabetes; thus, the proposed research will provide fundamental knowledge about diabetes that is relevant to public health. Results from this project are also expected to provide significant insights about using small-molecule probes of TALK-1 channels as therapies for treating diabetes. Thus, the proposed research is relevant to NIH?s mission that pertains to developing fundamental knowledge that will help reduce the burdens of human illness.
Filed on February 09, 2018.
Tell us what you know about C. David Weaver's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “C. David Weaver”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| C. David Weaver | Vanderbilt University | Conflict of Interest | WaveFront Biosciences | Value cannot be readily determined |
| C. David Weaver | Vanderbilt University | Conflict of Interest | WaveFront Biosciences | $5,000 - $9,999 |
| C. David Weaver | Vanderbilt University | Conflict of Interest | WaveFront Biosciences | $5,000 - $9,999 |
| C. David Weaver | Vanderbilt University | Conflict of Interest | WaveFront Biosciences | $5,000 - $9,999 |
| C. David Weaver | Vanderbilt University | Conflict of Interest | WaveFront Biosciences | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.